The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis

BJU International

Volumn 89, Issue 7, 2002, Pages 710-713

  Chen, S S ^a   Chen, K K ^a   Lin, A T L ^a   Chang, Y H ^a   Wu, H H ^a   Chang, L S ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

FSH; LH; Prognosis; Prolactin; Prostatic carcinoma; Testosterone

Indexed keywords

ANTINEOPLASTIC AGENT; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN BLOOD LEVEL; PROSTATE CARCINOMA; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; FOLLICLE STIMULATING HORMONE; HORMONES; HUMANS; LUTEINIZING HORMONE; MALE; PROLACTIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TESTOSTERONE; TREATMENT OUTCOME;

EID: 0036224481     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.02733.x     Document Type: Article

References (28)

1. Studies on prostatic cancer, the effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
2. Hormonal therapy of prostatic cancer
3. An exponential model relating censored survival data and concomitant information for prostatic cancer patients
4. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate
5. Analysis of prognostic factors for prostatic cancer in the VACURG studies
6. Carcinoma of the prostate: Relationship of pretreatment hormone levels to survival
7. Hormone patterns in prostatic cancer II. Correlation with primary response to endocrine treatment
8. Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer
9. A prognostic index for the clinical management of patients with advanced prostatic cancer: A British prostate study group investigation
10. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging
11. Carcinoma of the prostate - Prognostic features in 20% of radical prostatectomies
12. Effects of pituitary hormones on the prostate
13. Steroid hormone concentrations in relation to patient prognosis and prostate tumor grade
14. Advanced cancer of the prostate - Does pretreatment Leydig cell function determine the response to therapy?
15. Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate
16. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer
17. Cancer of the prostate in men less than 50 years old. An analysis of 51 cases
18. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients
19. The clinical usefulness of serum PSA after hormonal therapy of metastatic prostate cancer
20. Endogenous hormones as a major factor in human cancer
21. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration
22. Prospective study of sex hormone levels and risk of prostate cancer
23. Andropause
24. Plasma testosterone levels in patients with prostatic carcinoma before and after treatment
25. Effect of hormonal therapy on plasma testosterone levels in prostatic cancer
26. High serum prolactin associated with poor prognosis in carcinoma of the prostate
27. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCap, DU145, and PC3 models of the human prostate
28. A case for synchronous reduction of testicular androgen and prolactin for the treatment of advanced carcinoma of the prostate